Product Description
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Germany | Italy | Pakistan | Portugal | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: CHU de Bordeaux
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
REMODEL'ASTHME | P2 |
Completed |
Asthma |
2012-07-01 |
2019-03-18 |
Treatments |
|
Remodel'asthme | P2 |
Active, not recruiting |
Asthma |
2012-06-24 |
2025-07-09 |
Treatments |